Nexien BioPharma (OTCMKTS:NXEN) and Innovus Pharmaceuticals (OTCMKTS:INNVD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.
Earnings & Valuation
This table compares Nexien BioPharma and Innovus Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Nexien BioPharma | N/A | N/A | $-2,670,000.00 | N/A | N/A |
Innovus Pharmaceuticals | $23.99 million | 0.29 | $-8,280,000.00 | ($4.16) | -0.72 |
Nexien BioPharma has higher earnings, but lower revenue than Innovus Pharmaceuticals.
Risk and Volatility
Nexien BioPharma has a beta of -701.47, meaning that its stock price is 70,247% less volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals has a beta of 2.89, meaning that its stock price is 189% more volatile than the S&P 500.
Institutional and Insider Ownership
10.4% of Innovus Pharmaceuticals shares are owned by institutional investors. 30.6% of Nexien BioPharma shares are owned by company insiders. Comparatively, 16.4% of Innovus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and price targets for Nexien BioPharma and Innovus Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Nexien BioPharma | 0 | 0 | 0 | 0 | N/A |
Innovus Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Profitability
This table compares Nexien BioPharma and Innovus Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Nexien BioPharma | N/A | -16,049.80% | -6,651.95% |
Innovus Pharmaceuticals | -34.51% | -682.54% | -78.57% |
Summary
Innovus Pharmaceuticals beats Nexien BioPharma on 5 of the 8 factors compared between the two stocks.